YOLFTbeta
Genelux Corporation Common Stock

Genelux Corporation Common Stock

GNLX · NASDAQ · Healthcare / Biotechnology

1.87USD-0.03 (-1.84%)

Price History

Full chart

Market Stats

Previous Close1.90
Open1.92
Day Range1.83 – 1.96
52-Week Range2.29 – 8.54
Volume179.40K
Market Cap112.21M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.86
Dividend Yield0.00%
Beta0.56
50-Day Avg2.69
200-Day Avg2.90

About

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Thomas D. Zindrick J.D.
  • Employees25
  • Headquarters2625 Townsgate Road, Westlake Village, CA, United States, 91361, USA
  • Websitehttps://www.genelux.com

Leadership

  • Mr. Thomas D. Zindrick J.D.Chairman, CEO & President · b. 1960
  • Mr. Matthew Pulisic M.B.A.CFO and Principal Financial & Accounting Officer · b. 1984
  • Dr. Joseph Cappello Ph.D.Chief Technical Officer · b. 1957
  • Dr. Yong Yu Ph.D.Chief Scientific Officer · b. 1972
  • Mr. Eric Groen J.D.General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development · b. 1971
  • Mr. Ralph Smalling B.Sc.VP & Head of Regulatory Affairs · b. 1955
  • Dr. Jason B. Litten M.D.Chief Medical Officer · b. 1974

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0011.07M170.00K8.00K8.00K
Growth (%)-----98.46%-95.29%0.00%
Cost of Revenue477.00K658.00K895.00K968.00K1.02M903.00K574.00K
Gross Profit-477.00K-658.00K-895.00K10.10M-848.00K-895.00K-566.00K
Gross Margin---91.25%-498.82%-11187.50%-7075.00%
Operating Expense10.39M11.76M13.72M13.11M23.32M30.80M32.65M
Operating Income-10.87M-12.42M-14.61M-3.01M-24.16M-31.70M-33.21M
Operating Margin----27.22%-14214.71%-396200.00%-415175.00%
EBITDA-10.49M-11.76M-13.67M-1.73M-26.46M-28.97M-31.57M
EBITDA Margin----15.64%-15562.94%-362075.00%-394637.50%
Net Income-11.63M-14.86M-17.80M-5.21M-28.30M-29.87M-32.15M
Net Income Margin----47.05%-16645.29%-373362.50%-401812.50%
R&D7.53M6.23M6.32M9.08M12.77M19.00M19.85M
R&D as % of Total Revenue---82.02%7510.00%237475.00%248137.50%
Interest Expense761.00K1.22M1.81M1.41M3.97M0-
Interest Expense % of Total Revenue---12.72%2337.65%0.00%-

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.28M14.01M8.13M5.53M27.89M34.72M19.03M
Total Liabilities28.09M36.66M41.24M41.31M8.42M8.44M7.48M
Total Equity-24.81M-22.66M-33.11M-35.78M19.47M26.27M11.54M
Cash425.00K11.35M4.50M397.00K9.42M8.56M5.33M
Total Debt17.97M26.06M25.31M26.35M2.52M1.87M1.69M
Net Debt17.55M14.71M20.82M25.96M-6.90M-6.70M-3.65M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.22M-7.21M-6.58M-3.57M-20.27M-21.23M-25.27M
Investing Cash Flow-1.77M-20.00K-49.00K-49.00K-14.72M-8.13M12.14M
Financing Cash Flow7.89M18.15M-270.00K-478.00K44.02M28.51M9.89M
Capital Expenditure1.77M20.00K49.00K49.00K1.02M381.00K1.10M
Free Cash Flow-8.99M-7.22M-6.58M-3.62M-21.30M-21.61M-26.37M
FCF to OCF124.52%100.28%100.00%101.37%105.06%101.79%104.35%

Earnings

Report DateJun 24, 2022Sep 19, 2022Mar 29, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 29, 2024May 9, 2024Aug 14, 2024Nov 14, 2024Mar 28, 2025May 6, 2025Aug 7, 2025Nov 5, 2025Mar 20, 2026May 7, 2026Aug 13, 2026Nov 4, 2026
EPS Estimate0.000.000.00-0.16-0.15-0.15-0.19-0.21-0.21-0.19-0.25-0.24-0.22-0.23-0.22-0.20-0.20-0.20
EPS Actual-0.16-0.12-0.12-0.53-0.23-0.20-0.25-0.29-0.22-0.19-0.25-0.21-0.20-0.21-0.24-0.20-0.21-
Surprise----231.25%-53.33%-33.33%-31.58%-38.10%-4.76%0.00%0.00%12.50%9.09%8.70%-9.94%0.00%-5.00%-
Timing--After-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours---After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap112.21M
Enterprise Value97.32M
Trailing P/E0.00
Forward P/E0.00
Price / Sales14026.05
Price / Book7.05
EPS-0.86
Book Value0.361
Revenue (TTM)8.00K
Gross Profit (TTM)8.00K
EBITDA-36.28M
Profit Margin0.00%
Operating Margin-455275.00%
Return on Equity-177.93%
Return on Assets-77.89%
Shares Outstanding45.25M
Shares Float36.44M
Beta0.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 18.83
  • Strong Buy
    3
  • Buy
    2

Ownership Breakdown

Institutions
31.01%
Insiders
12.87%
Retail / Other
56.12%

Top Institutional Holders

  • WOODWARD DIVERSIFIED CAPITAL, LLC
    2.26M5.00%
  • Vanguard Capital Management, LLC
    1.70M3.75%
  • Bleichroeder LP
    1.38M3.05%
  • Geode Capital Management, LLC
    453.76K1.00%
  • BlackRock Inc
    405.87K0.90%
  • Bank of America Corp
    323.87K0.72%
  • F.L.Putnam Investment Management
    280.90K0.62%
  • Vanguard Fiduciary Trust Co
    251.61K0.56%
  • CM Management, LLC
    250.00K0.55%
  • Global Retirement Partners, LLC.
    227.85K0.50%
  • Northern Trust Corp
    164.46K0.36%
  • State Street Corp
    145.85K0.32%
  • Provident Wealth Management, LLC
    144.91K0.32%
  • LPL Financial Corp
    139.04K0.31%
  • UBS Group AG
    122.58K0.27%
  • LifeSteps Financial, Inc.
    121.97K0.27%
  • Advisor Group Holdings, Inc.
    119.01K0.26%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.19M2.67%
  • Fidelity Extended Market Index
    208.95K0.47%
  • iShares Micro-Cap ETF
    137.14K0.31%